Immunotherapy Models

Syngeneic Models

Syngeneic mouse models enable researchers to evaluate immunotherapy candidates in a fully functional immune system. This is done by transferring a mouse tumor cell line into an inbred mouse strain with an intact immune system.

TD2 Syngeneic models are:

  • Fully Characterized – Syngeneic tumor models are fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors.
  • One Consistent Host — through 16S ribosomal RNA (rRNA) gene sequencing launched before the study even begins, we define the microbiome at the onset, which enables your project focused access to a known and stable host from start to finish.
  • Find Effector Cells — through multi-parameter flow cytometry, we can characterize phenotypic immune cell population changes post-treatment.

Learn more about our syngeneic services.

Contact our experts to help advance your immunotherapy candidate with our trusted preclinical research services.

    Available Syngeneic Models

    Cancer Type Syngeneic Line Expression Data Available
    PD-1 PD-L1 PD-L2 CTLA4 Other
    Bladder MB-49
    MBT-2
            
    Brain GL261        
    Breast 4T1
    4T1-Luc
    EMT-6
    EO771
                  
    Colon Colon 26-Luc
    colon 26
    CT-26
    MC-38
                       TIM-3, OX40
    CD40
    Hematologic EL-4 (Lymphoma)
    MPC-11 (Myeloma)
    Growth Kinetics
    Growth Kinetics
    Hepatoma Hepa 1-6      
    Lung KLN205
    LL/2
    LL/2-Luc
    TC-1 (HPV-Associated)
                      Growth Kinetics
    Ovarian ID8-Luc Growth Kinetics
    Mastocytoma P815 Growth Kinetics
    Pancreas Pan02
    Pan02 (Orthotopic)
           TIM-3, GITR
    Renal RENCA      
    Sarcoma K7M2 (IV) Growth Kinetics
    Skin B16-F1
    B16-F10
    B16-BL6
                   

    Figure 1. Growth curve response to standard of care treatments in orthotopic E0071 in C57BL/6 mice, subcutaneous MC38 in C57BL/6 mice, and subcutaneous CT-26 in balb/c mice in

    E0771 Murine Breast Tumor Model

    E0771 Murine Breast Tumor Model

    MC38 Murine Colon Tumor Model

    MC38 Murine Colon Tumor Model

    CT-26 Murine Colon Tumor Model

    CT-26 Murine Colon Tumor Model

    Immuno-oncology

    Comprehensive preclinical services for immuno-oncology.

    TD2’s extensive knowledge of CAR-T in both solid and hematologic tumors enables rapid evaluation of your CAR-T cell therapy, moving your therapeutic program forward to the clinic.

    Large panel of human and murine tumor models

    Cell therapy models


    • 8 years of experience in cell therapy
    • Expertise includes: CAR-T, NK-CAR, IPS-NKs, Macrophages

    Humanized mice


    • Human PBMCs or effector cell engraftment
    • Sourced CD34+ humanized mice

    Get Started

    Work with a team who believes in your research as much as you do.

    Are you ready to start your preclinical Adoptive Cell Transfer Therapy studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.